[System analysis of the relationship between the metabolism of vitamins by micro-biota and the survival of the positive microflora of the digestive tract].
A perspective direction of the treatment of dysbacteriosis is the use of so-called metabolic prebiotics--products of metabolism of positive flora (for example, water substrate of the products of metabolism of E. coli, S. faecalis, L. acidophilus, L. helveticus (strains of DSM), out of which, as known, drug Hylak Forte is made. Our earlier systematic analysis of metabolomics, representatives of positive microflora, pointed to the fact that the latter contain specific biochemical mechanisms for biosynthesis and processing of a number of vitamins. In the present paper the results of a systematic analysis of the effects of vitamins B2, B6 and K on the survival of the representatives of the positive microflora on the basis of the substrate of metabolic products of positive flora have been presented. The results of the analysis allow us clarify the molecular mechanisms of the therapeutic effects of this drug with a very complex structure and confirm the available clinical data and are an important foundation for subsequent microbiological research. Metabolites in the preparation composition contribute to the normalization of metabolism of pyridoxalphosphate (vitamin B6), flavin adenin dinucleotide (FAD, a derivative of vitamin B2) and nicotinamide dinucleotide (NAD, a derivative of vitamin B3)--cofactors of enzymes that have a significant impact on the survival of microbiota. The proposed molecular mechanisms also indicate on a possible synergies between certain vitamins and micro elements, on the one hand, and molecular components of the preparations on the basis of waste products of microbiota on the other.
O A
OA
Gromova
I Iu
IIu
Torshin
E V
EV
Garas'ko
O A
OA
Limanova
T R
TR
Grishina
K V
KV
Rudakov
D004066:Digestive System Diseases / Q000188:drug therapy / Q000382:microbiology; D013293:Enterococcus faecalis / Q000378:metabolism*; D004926:Escherichia coli / Q000378:metabolism*; D041981:Gastrointestinal Tract / Q000187:drug effects / Q000382:microbiology*; D006801:Humans; D007778:Lactobacillus / Q000378:metabolism*; D055442:Metabolome; D050296:Microbial Viability; D008954:Models, Biological; D008958:Models, Molecular; D009930:Organic Chemicals / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use; D056692:Prebiotics; D014815:Vitamins / Q000096:biosynthesis / Q000737:chemistry / Q000378:metabolism*
C071735:Hylak; D009930:Organic Chemicals; D056692:Prebiotics; D014815:Vitamins